A detailed history of Entry Point Capital, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Entry Point Capital, LLC holds 53,763 shares of BCRX stock, worth $406,985. This represents 0.24% of its overall portfolio holdings.

Number of Shares
53,763
Holding current value
$406,985
% of portfolio
0.24%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$6.41 - $8.69 $344,620 - $467,200
53,763 New
53,763 $408,000
Q1 2024

May 14, 2024

BUY
$4.89 - $7.65 $182,274 - $285,153
37,275 Added 689.77%
42,679 $217 Million
Q4 2023

Feb 14, 2024

BUY
$4.98 - $6.77 $26,911 - $36,585
5,404 New
5,404 $32.4 Million

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Entry Point Capital, LLC Portfolio

Follow Entry Point Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Entry Point Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Entry Point Capital, LLC with notifications on news.